ALX Oncology Holdings Inc.
NASDAQ:ALXOBiotechnology
-$0.03 today
- Market cap
- $134.14M
- Beta
- 0.45
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$1.64
Volume 0.56M
Average 1.07M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
ALX Oncology Holdings Inc.
NASDAQ:ALXO
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Kymera Therapeutics, Inc. NASDAQ:KYMR | $10.89B | $127.57 | Not rated | -28.3 | +86.87% |
Stoke Therapeutics, Inc. NASDAQ:STOK | $1.75B | $26.68 | Undervalued | -11.1 | -6.29% |
Monte Rosa Therapeutics, Inc. NASDAQ:GLUE | $800.67M | $9.37 | Not rated | -9.1 | -35.86% |
Annexon, Inc. NASDAQ:ANNX | $642.26M | $3.92 | Not rated | -4.8 | -13.30% |
Bicycle Therapeutics plc NASDAQ:BCYC | $236.22M | $3.37 | Not rated | -1.3 | -50.24% |
Nkarta, Inc. NASDAQ:NKTX | $85.23M | $1.19 | Not rated | -2.0 | -35.75% |
Tenaya Therapeutics, Inc. NASDAQ:TNYA | $79.59M | $0.35 | Not rated | -1.3 | -74.21% |
Continue the stock analysis
Jump to another research area for this company.